报价延迟最少15分钟:2025/09/04 04:00 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.49
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.09/-6.33
|
|
企业价值
17.08M
|
| 资产负债 |
|
每股账面净值
1.08
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
8.00K
|
|
每股收益
0.04
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/04 04:00 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformativetreatments for serious diseases. |
